Emergent BioSolutions
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Emergent BioSolutions sits in the top decile of US sponsors by registered trial count (#484 of 15,742 sponsors by registered trial count).
Emergent BioSolutions: 34 sponsored US clinical trials, none currently recruiting.
Emergent BioSolutions sponsors 34 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 30 completed. 5 of these trials are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Smallpox, with 3 trials.
Top-decile sponsor footprint
Emergent BioSolutions ranks in the top decile of sponsors by registered trial count (#484 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
30 of 34 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
34 total, page 1 of 1
Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
NCT05935917
Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults
NCT05377255
Study of SIAN Nasal Spray in Healthy Adults
NCT05194358
A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
NCT05142306
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
NCT04661839
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
NCT04067011
VELOCITY: An Anthrax Vaccine Clinical Study
NCT03877926
Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A
NCT03315104
A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047
NCT03160339
Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
NCT02696291
Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults
NCT02771730
Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed
NCT02339155
Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
NCT02061358
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
NCT01979406
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
NCT01770743
Ciprofloxacin BioThrax Co-Administration Study
NCT01753115
BioThrax® (Anthrax) Vaccine in Pregnancy Registry
NCT01653392
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
NCT01491607
ACAM2000® Myopericarditis Registry
NCT01395082
Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults
NCT01263691
VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV
NCT01158157
Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)
NCT01202695
Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1
NCT01006798
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
NCT01540929
Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)
NCT01311674
Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
NCT00845650
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
NCT00928577
Safety Surveillance Study of ACAM2000® Vaccinia Vaccine
NCT00927719
Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
NCT00679172
Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle
NCT00636519
Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum
NCT00448253
Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses
NCT00360737
Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
NCT00053495
Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults
NCT00053482
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 17 |
| Phase 2 | 7 |
| Phase 3 | 4 |
| Phase 4 | 1 |
Therapeutic Areas
How the Emergent BioSolutions early-phase archive is shaped
34 indexed studies, none listed as recruiting (0% open); 30 completed (88%).
Phase mix: 5 late (III/IV) vs 24 early (I/II) (early-phase heavy).
Top condition: Smallpox (3 trials), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Emergent BioSolutions: archived-pipeline peers nationwide
Peers matched on 34 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Emergent BioSolutions sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 34 archived trials
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 34 trials · 38% recruiting
- American Regent · 34 trials · 0% recruiting
- Amicus Therapeutics · 34 trials · 15% recruiting
- Cochlear · 34 trials · 12% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Emergent BioSolutions page
34 registered trials is a research-attention snapshot, not an endorsement of Emergent BioSolutions or any single study.
- None of Emergent BioSolutions's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Smallpox is the condition Emergent BioSolutions studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Smallpox trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Emergent BioSolutions pipeline card: 34 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.